Anakinra for treating Still’s disease - guidance (TA685)

NICE recommends anakinra for Still's disease with moderate/high disease activity, or continued disease activity after NSAIDs or glucocorticoids with set restrictions.

SPS commentary:

It is only recommended for:

    • Adult-onset Still's disease that has responded inadequately to 2 DMARDs,
    • Systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD.

 

National Institute for Health and Care Excellence